Legacy Capital Group California, Inc. Gilead Sciences, Inc. Transaction History
Legacy Capital Group California, Inc.
- $301 Billion
- Q3 2024
A detailed history of Legacy Capital Group California, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Legacy Capital Group California, Inc. holds 6,062 shares of GILD stock, worth $570,494. This represents 0.17% of its overall portfolio holdings.
Number of Shares
6,062
Previous 6,474
6.36%
Holding current value
$570,494
Previous $444 Million
14.42%
% of portfolio
0.17%
Previous 0.16%
Shares
7 transactions
Others Institutions Holding GILD
# of Institutions
1,926Shares Held
992MCall Options Held
10.5MPut Options Held
9.75M-
Black Rock Inc. New York, NY121MShares$11.4 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$10.9 Billion0.18% of portfolio
-
Capital World Investors Los Angeles, CA76.5MShares$7.2 Billion1.03% of portfolio
-
Capital Research Global Investors Los Angeles, CA61.8MShares$5.82 Billion1.12% of portfolio
-
State Street Corp Boston, MA60.2MShares$5.66 Billion0.21% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $118B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...